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Antifungal activityAbstract A novel series of Schiff bases 4a–n was prepared from 2-hydrazinyl-N-(2-(1-hydrox-
ycyclohexyl)-2-(4-methoxyphenyl) ethyl)acetamide. Thiazolidinone 5a–n derivatives were prepared
from the reaction of Schiff base and thioglycolic acid. The structures of the synthesized compounds
were assigned on the basis of elemental analysis, IR, 1H NMR, 13C NMR and Mass spectral data.
All the compounds were screened against different strains of bacteria and fungi. These active com-
pounds impelled us to study their antitubercular activity. Compounds 4b, 5a, 5b, 5d, 5e, 5f, 5k, 5l
and 5n emerged as promising antimicrobials. It was also observed that the promising antimicrobials
have proved to be better antituberculars. Compound 5k showed better antitubercular activity com-
pared to Rifampicin.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Tuberculosis (TB), a disease long considered substantially
eradicated in the developed countries, has resurged dramati-
cally in the last decades, establishing itself as one of the infec-
tious diseases resulting in the highest number of human deathsworldwide (World Health Organization, 2006; Ballell et al.,
2005; Janin, 2007). Likely, the ﬁrst underlying reason for such
escalation in number of infections with the TB pathogen,
Mycobacterium tuberculosis (MT), is the deadly synergy with
human immunodeﬁciency virus (HIV) indeed, an impressive
number of HIV-infected individuals succumb to MT aggres-
sion (Morris et al., 1995). The second, important cause is the
emergence of multi-drug resistant strains (MDR) of MT (Ball-
ell et al., 2005; Janin, 2007; Morris et al., 1995; Telzak et al.,
1995; Basso and Blanchard, 1998; Bastian and Colebuuders,
1999), together with the spread of severe opportunistic dissem-
inated infections produced by Mycobacterium other than
tuberculosis (MOTT), particularly Mycobacterium avium
(Inderlied et al., 1993).
The standard therapy (Janin, 2007) for TB includes isonia-
zid, targeting both the NADH-dependent enoyl reductase
Synthesis and pharmacological studies of 1-(2-amino-1-(4-methoxyphenyl) ethyl) cyclohex anol S805(InhA) and the 3-oxoacyl ACP synthase (KasA) (Mdluli et al.,
1998; Rozwarski et al., 1998) and Rifampicin, a well character-
ized inhibitor of the DNA-dependent RNA-polymerase (Cole,
1994). There are two basic approaches to develop a new drug
for TB: (i) synthesis of analogs, modiﬁcations or derivatives of
existing compounds for shortening and improving TB treat-
ment and, (ii) searching novel structures, that the TB organism
has never been presented with before, for the treatment of mul-
ti-drug resistant TB (Crabb, 2002).
To pursue this goal, our research efforts are directed to ﬁnd
new chemical classes of antitubercular active agents with dif-
ferent modes of action. Thiazolidin-4-ones are an important
group of heterocyclic compounds, having valuable biological
activities in the areas of medicine. Recently, antimicrobial
and antimycobacterial activities (de Aquino et al., 2008; Verma
and Saraf, 2008; Ku¨c¸u¨kgu¨zel et al., 2006) of this framework
containing compounds were explored well whereas, their 2,3-
disubstituted analogs have proved to be predominantly effec-
tive non-nucleoside HIV reverse transcriptase inhibitors
(Barreca et al., 2001).
Thiazolidinone and its derivative are known to possess a
variety of physiological properties; viz. analgesic, local and
spiral anesthetics, antibacterial, (Mistry and Desai, 2004;
Sayyed et al., 2006) anti-inﬂammatory, (Yadav et al., 2005)
antitubercular, (Patel et al., 2006) anticancer, anti HIV (Bhatt
et al., 1994) and fungicidal (Hui-Ling et al., 2000) activities.
After an extensive literature search, it was observed that, till
date enough effort has not been made to combine these two
moieties as a single molecular scaffold and to identify new can-
didates that may be of value in designing new, potent, selective
and less toxic antitubercular and antimicrobial agents. In view
of this data, we reported the synthesis of new thiazolidinone
and Schiff base which possessed a wide variety of biological
activities encouraging antitubercular activity against M. tuber-
culosis H37Rv and antimicrobial activity.
The present work deals with the synthesis of the title com-
pounds starting from 1-(2-amino-1-(4-methoxyphenyl) ethyl)
cyclohexanol, followed by their antimicrobial, antifungal and
antitubercular screening.
2. Chemistry
1-(2-Amino-1-(4-methoxyphenyl) ethyl) cyclohexanol (1), on
condensation with chloroacetyl chloride yielded 2-chloro-N-
(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetam-
ide (2), which on amination with hydrazine hydrate yielded
in turn 2-hydrazinyl-N-(2-(1-hydroxycyclohexyl)-2-(4-
methoxyphenyl) ethyl) acetamide (3). Compound 3, on con-
densation with various aromatic aldehydes afforded a series
of 2-(2-benzylidenehydrazinyl)-N-(2-(1-hydroxycyclohexyl)-2-
(4-methoxyphenyl)ethyl) acetamides 4a–n, which upon reac-
tion in the presence of Thioglycolic acid and dimethyl formam-
ide yielded 2-(4-oxo-2-substituted phenylthiazolidin-3-
ylamino)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)
ethyl) acetamide 5a–n (Scheme 1).
3. Biology
The MICs of synthesized compounds were carried out by
broth micro dilution method as described by the European
Society of Clinical Microbiology and Infectious Diseases(ESCMID) (Husbands et al., 1984). Antibacterial activity
was screened against one gram positive bacterium (Staphylo-
coccus aureus ATCC 6538P) and two gram negative bacteria
(Escherichia coli ATCC 8739, and Pseudomonas aeruginosa
ATCC 9027). Ampicillin and Penicillin-G were used as a stan-
dard antibacterial agent. Antifungal activity was screened
against three fungal species Candida albicans ATCC 10231,
Aspergillus niger ATCC 16404 and A. clavatus ATCC 9600.
Greseofulvin was used as a standard antifungal agent.
All ATCC cultures were collected from the National Chem-
ical Laboratory, Pune and tested against the above mentioned
known drugs. Mueller Hinton broth was used as a nutrient
medium to grow and dilute the drug suspension for the test.
Inoculums’ size for the test strain was adjusted to 108 CFU
(Colony Forming Unit) per milliliter by comparing the turbid-
ity. DMF was used as diluents to get the desired concentration
of drugs to test upon standard bacterial strains. MIC of com-
pounds was determined against M. tuberculosis H37Rv strain
by using Lowenstein–Jensen medium (conventional method)
as described by Rattan (EUCAST; Rattan, 2000).
4. Result and discussion
4.1. Analytical results
A series of analogs has been synthesized in good yields by
using the synthetic route as outlined in Scheme 1. IR, 1H
NMR, 13C NMR and mass spectral data are in well agreement
with the proposed structures of all newly synthesized
compounds.
The IR spectra of Compound 3 showed a broad stretching
band around 3425 and 3200 cm1 for NH and NH2 with
1H
NMR a singlet at d 2.1 and d 8.1 accounted for NH2 and NH
accordingly. Mass spectrum of compound 3 displayed a molec-
ular ion peak at m/z 321, conﬁrmed its molecular weight. The
synthesized compounds 4a–n and 5a–n were conﬁrmed by IR,
NMR and mass spectra. A typical sharp characteristic absorp-
tion band for –C‚O was observed at mmax 1717. The bands of
–C‚N of Schiff base derivatives clearly appeared at
1570 cm1. In 1H NMR, a singlet at d 8.2 attributed to the
N‚CH–protonswhile in the 13CNMRspectra, the high d value
at 144.1 ppm attributed to the N‚CH– group present in Schiff
base. In 1HNMRdoublet at 3.55 value and in 13CNMR spectra
54.52 ppm indicate the presence of –CO‚CH2–NH– group.
In 1H NMR, a singlet at d 5.90 and in 13C NMR spectra
value of 57.10 attributed to the presence of –CH–S of thiazo-
lidinone ring. Mass spectrum of 4b displayed a molecular ion
peak at m/z 514, conﬁrmed its molecular weight.4.2. Biological results
The antibacterial screening results are summarized in
Table 1.The results revealed that substituted Schiff base
showed moderate activity against all the bacterial strains ex-
cept compound 4b having 4-methoxy substituent showed good
activity against S. aureus and E. coli, while thiazolidinone
exhibited good activity against S. aureus and P. aeruginosa.
Most of thiazolidinone showed good activity (256 lg/ml) while
compounds 5e and 5f containing 2,3,4-trimethoxy and 2-
chloro substituents possessed pronounced activity (128 lg/
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Scheme 1 Synthetic protocol for 2-(4-oxo-2-substituted phenylthiazolidin-3-ylamino)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)
ethyl) acetamide 5a–n.
S806 V. Mahyavanshi et al.ml) against S. aureus. Compounds 5a, 5b and 5d having 4-hy-
droxy, 4-methoxy and 2,3-dichloro substituents showed good
activity (128 lg/ml) then other compounds against Streptococ-
cus pyogenes. Compound 5k containing 4-hydroxy 3-methoxy
substituent has higher activity (16.0 lg/ml) against E. coli and
(32 lg/ml) against P. aeruginosa. Good activity was observed
with compounds 5a, 5e, 5g, 5l and 5m containing 4-hydroxy,
2,3,4-trimethoxy, 4-nitro, 3-bromo and 2-nitro substituents
while others displayed moderate activity against E. coli. Com-
pounds 5e, 5f and 5j having 2,3,4-tri methoxy, 2-dichloro and
N,N-dimethyl substituents showed good activity (128 lg/ml)
whereas others displayed moderate activity against P. aerugin-
osa. Compounds 5a, 5b, 5d, 5k, 5l and 5n exhibited very good
activity against gram positive bacteria whereas 5b, 5e, 5f and
5k showed very good activity toward gram negative bacteria.
The results of antifungal activity are summarized in Table 2.
The results showed that Schiff base 4a–n possessed good activ-
ity (256–512 lg/ml) against C. albicans. Compounds 4a–n dis-
played moderate to weak activity (256–512 lg/ml) against A.
niger. Compounds 5f, 5h and 5n having 2-chloro, 3,4,5-tri-
methoxy and 3-chloro substituent exhibited better activity
(128 lg/ml) whereas other compounds showed good activity(256 lg/ml) except 5g, 5j and 5l against C. albicans. All the
compounds showed weak activity against A. niger and Asper-
gillus clavatus.
The encouraging results from the antibacterial studies that
impelled us to go for preliminary screening of synthesized com-
pounds against M. tuberculosis are summarized in Table 3.
Compound 4b containing 4-methoxy substituent showed better
activity (64 lg/ml) against M. tuberculosis and compounds 5b,
5f, 5l and 5n showed good activity (32–64 lg/ml) which is
attributed due to 4-methoxy, 2-chloro, 3-bromo and 3-chloro
substituents whereas compound 5k which is having 4-hydroxy
3-methoxy substituent on thiazolidinone ring showed better
activity (16 lg/ml). Due to the better activity against tested
microorganisms and mycobacteria, compound 5k has been se-
lected for further development and studies to acquire more
information about structure–activity relationships that are in
progress in our laboratories.
5. Conclusion
A series of newer analogs of thiazolidinone were synthesized
by introduction of Schiff base to thiazolidinone using aromatic
Table 1 Minimum inhibitory concentrations (MICs, lg/ml).
Compounds Minimal bactericidal concentration lg/ml
Gram positive Gram negative
S. aureus ATCC 6538P S. pyogenes ATCC 8668 E. coli ATCC 8739 P. aeruginosa ATCC 9027
4a 512 512 128 512
4b 256 256 64 128
4c 512 256 512 512
4d 256 512 128 256
4e 512 256 256 512
4f 512 256 512 512
4g 512 512 512 512
4h 512 128 512 512
4i 512 512 256 256
4j 512 512 256 512
4k 128 256 128 128
4l 512 512 512 512
4m 512 512 256 512
4n 512 256 512 256
5a 128 128 256 256
5b 128 128 64 64
5c 512 128 256 512
5d 128 128 128 256
5e 256 256 256 128
5f 256 256 512 128
5g 512 512 256 512
5h 128 128 64 512
5i 512 256 128 256
5j 512 256 128 128
5k 64 256 16 32
5l 128 128 256 256
5m 256 256 256 512
5n 128 128 512 256
Ampicillin 250 100 100 100
Synthesis and pharmacological studies of 1-(2-amino-1-(4-methoxyphenyl) ethyl) cyclohex anol S807aldehyde in the presence of acetic acid and assessed for their
antimicrobial and antituberculosis activity. The antibacterial
data indicated that the analogs with halogen, methoxy and ni-
tro substituents emerged as promising antimicrobials showed
moderate to better activity while analogs bearing chloro substi-
tuent showed better antifungal activity. It was also observed
that the promising antimicrobials had proved to be better anti-
tuberculars. Speciﬁcally, compound 5k, due to its better activ-
ity against H37Rv strain, would be the best choice for the
preparation of new derivatives in order to improve antituber-
cular activity in the future.6. Experimental
6.1. Chemistry
All chemicals were of analytical grade and used directly. Melt-
ing points were determined in PMP–DM scientiﬁc melting
point apparatus and are uncorrected. The purity of com-
pounds was checked by TLC using Merck silica gel 60F254
and visualized by exposure to iodine vapors or UV light. IR
spectra were recorded on a Perkin–Elmer RX 1 FTIR spectro-
photometer, using potassium bromide pellets, the frequencies
are expressed in cm1. The 1H NMR and 13C NMR spectra
were recorded with a Bruker Avance II 400 NMR spectrome-
ter, using tetramethylsilane as the internal reference, with chlo-roform (CDCl3) as solvent. The chemical shifts are reported in
parts per million (d ppm). Elemental analyses were performed
on a Heraeus Carlo Erba 1180 CHN analyzer. The mass spec-
tra were recorded on micromass Q–T of micro (TOFMS ES·).
All spectral data were consistent with the proposed structure
and micro analysis within ±0.4% of theoretical values.
6.1.1. Procedure for the synthesis of 2-chloro-N-(2-(1-hydrox-
ycyclohexyl)-2-(4-methoxyphenyl)ethyl)acetamide (2)
A mixture of 1-(2-amino-1-(4-methoxyphenyl) ethyl) cyclohex-
anol (1) (Husbands et al., 1984) (0.1 mol) and chloroacetyl
chloride (0.1 mol) in Toluene (30 ml) was stirred at 30–35 C
in the presence of sodium carbonate (0.1 mol) for about
6.0 h. Completion of reaction was monitored by T.L.C (tolu-
ene/acetone, 5:5). The excess solvent was distilled off and then
the remaining residue was poured into ice cold water. The sep-
arated solid was ﬁltered, washed and recrystallized from etha-
nol to have a white color solid product. Yield 90%; m.p. 90 C.
6.1.2. Procedure for the synthesis of 2-hydrazinyl-N-(2-(1-
hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)acetamide (3)
A mixture of 2-chloro-N-(2-(1-hydroxycyclohexyl)-2-
(4-methoxyphenyl) ethyl) acetamide (2, 0.1 mol) and hydrazine
hydrate (0.1 mol) in methanol (30 ml) was reﬂuxed for about
6 h. Completion of reaction was monitored by T.L.C (tolu-
ene/acetone, 5:5). The mixture was then cooled down and
Table 2 Minimum inhibitory concentrations (MICs, lg/ml).
Compounds Minimal fungicidal concentration lg/ml
C. albicans ATCC 10231 A. niger ATCC 16404 A. clavatus ATCC 9600
4a 512 256 512
4b 512 512 256
4c 512 256 256
4d 512 256 512
4e 512 512 512
4f 256 512 512
4g 512 512 256
4h 256 256 256
4i 512 256 256
4j 512 512 512
4k 512 512 512
4l 512 512 256
4m 256 256 256
4n 512 256 256
5a 256 512 256
5b 256 256 128
5c 256 256 128
5d 256 128 256
5e 256 512 256
5f 128 256 512
5g 512 512 512
5h 128 256 256
5i 256 256 256
5j 512 512 512
5k 256 512 256
5l 512 512 512
5m 256 256 256
5n 128 256 256
Griseofulvin 500 100 100
S808 V. Mahyavanshi et al.pH was adjusted to 4.0 by addition of 10% Acetic acid. Prod-
uct was extracted in methylene dichloride by adjusting pH 9.0
by the addition of 10% sodium carbonate. Methylene dichlo-
ride was distilled out under vacuum to get colorless oil. Yield
70%.
6.1.3. General preparation of the compounds (4a–n)
A mixture of 2-hydrazinyl-N-(2-(1-hydroxycyclohexyl)-2-
(4-ethoxyphenyl) ethyl) acetamide (3, 0.01 mol), aromatic alde-
hyde (0.01 mol) and 2–3 drops of glacial acetic acid in metha-
nol (30 ml) was reﬂuxed for 5 h. The completion of reaction
was monitored by TLC (Eluent: toluene/acetone 5:5). The ex-
cess solvent was distilled off and the remaining residue was
then poured into ice cold water. The separated solid was ﬁl-
tered, washed and recrystallized from ethanol to give com-
pounds (4a–n).6.1.3.1. 2-(2-(4-Hydroxybenzylidene) hydrazinyl)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4a). Yield 77%; m.p. 180–182 C; light yellow color powder,
IR (KBr, cm1) 3470 (NH), 1719 (C‚O), 1654 (CONH), 1542
(N‚CH), 1H NMR: (400 MHz, CDCl3) d: 3.72 (s, 3H, Ar–
OCH3), 2.0 (d, 1H, –OH) (cyclohexanol), 1.4–1.68 (m, 10H,
–CH2 (cyclohexanol), 3.45 (dd, 1H, –CH), 3.61 (dd, –2H, –
CH2), 8.01 (d, 1H, –NH–C‚O), 3.55 (d, 2H, –C‚O, –CH2),
2.01 (d, 1H, NH-N), 8.2 (s, 1H, N‚CH), 7.41–6.82 (s, 1H,
Ar-OH), 6–8 (m, Ar–H, 1–8 H), 13C NMR: (50 MHz; CDCl3)
d: 55.8 (C–OCH3), 19.8–71.5 (Cyclohexane), 50.79 (CH), 36.4(–NH–CH2), 54.52 (O‚C–CH2), 144.1 (CH‚N), 116.4–
1601.0 (Aromatic), Anal. calcd for C24H31N3O4: C 67.74, H
7.34, N 9.87, O; found C 67.70, H 7.31, N 9.82.
6.1.3.2. 2-(2-(4-Methoxybenzylidene) hydrazinyl)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4b). Yield 72%; m.p. 210 C, off white color powder, IR
(KBr, cm1) 3465 (NH), 1715 (C‚O), 1648 (CONH), 1545
(N‚CH), 1H NMR: 3.75 (s, 3H, Ar–OCH3), 2.02 (d, 1H, –
OH) (cyclohexanol), 1.44–1.70 (m, 10H, –CH2 (cyclohexanol),
3.48 (dd, 1H, –CH), 3.65 (dd, –2H, –CH2), 8.05 (d, 1H, –NH–
C‚O), 3.54 (d, 2H, –C‚O, –CH2), 2.01 (d, 1H, NH–N), 8.11
(s, 1H, N‚CH), 6.7–8.0 (m, Ar–H, 1–8 H). 13C NMR
(50 MHz; CDCl3) d: 55.6 (C–OCH3), 19.9–71.9 (Cyclohexane),
50.75 (CH), 36.4 (–NH–CH2), 54.57 (O‚C–CH2), 143.8
(CH‚N), 114.4–163.0 (Aromatic), Anal. calcd for
C25H33N3O4: C 68.31, H 7.57, N 9.56; found C 68.29, H
7.52, N 9.50.
6.1.3.3. 2-(2-Benzylidenehydrazinyl)-N-(2-(1-hydrox-
ycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide (4c).
Yield 68%; m.p.92–95 C, Yellow color powder, IR (KBr,
cm1) 3460 (NH), 1700 (C‚O), 1664 (CONH), 541 (N‚CH),
1H NMR: 3.73 (s, 3H, Ar–OCH3), 2.04 (d, 1H, –OH) (cyclo-
hexanol), 1.45–1.69 (m, 10H, –CH2) (cyclohexanol), 3.48 (dd,
1H, –CH), 3.64 (dd, –2H, –CH2), 8.01 (d, 1H, –NH–C‚O),
3.59 (d, 2H, –C‚O, –CH2), 2.01 (d, 1H, NH–N), 8.15 (s,
1H, N‚CH), 7.0–7.9 (m, Ar–H, 1–8 H).13C NMR (50 MHz;
CDCl3) d: 55.9 (C–OCH3), 19.95–71.1 (Cyclohexane), 50.81
Table 3 Minimum inhibitory concentrations (MICs, lg/ml).
Compounds MIC values (lg/ml) of
M. tuberculosis H37Rv
Inhibition (%)
4a 512 99
4b 64 98
4c 512 98
4d 256 99
4e 256 99
4f 128 98
4g 512 98
4h 256 99
4i 512 99
4j 512 98
4k 64 98
4l 256 99
4m 512 99
4n 256 98
5a 256 98
5b 32 99
5c 256 99
5d 256 98
5e 128 98
5f 64 99
5g 256 99
5h 128 98
5i 256 98
5j 256 99
5k 16 99
5l 64 98
5m 128 98
5n 64 99
Rifampicin 40 98
Synthesis and pharmacological studies of 1-(2-amino-1-(4-methoxyphenyl) ethyl) cyclohex anol S809(CH), 36.4 (–NH–CH2), 54.50 (O‚C–CH2), 143.05 (CH‚N),
128.9.4–134.0 (Aromatic), Anal. calcd for C24H31N3O3:
C 70.39, H 7.63, N 10.26; found C 70.34, H 7.60, N 10.21.
6.1.3.4. 2-(2-(2, 3-Dichlorobenzylidene) hydrazinyl)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4d). Yield 64%; m.p. 210–215 C, Off white color powder,
IR (KBr, cm1) 3448 (NH), 1705 (C‚O), 1654 (CONH),
1534 (N‚CH), 1H NMR: 3.75 (s, 3H, Ar–OCH3), 2.06
(d, 1H, –OH) (cyclohexanol), 1.40–1.68 (m, 10H, –CH2
(cyclohexanol), 3.47 (dd, 1H, –CH), 3.66 (dd, –2H, –CH2),
8.01 (d, 1H, –NH–C‚O), 3.54 (d, 2H, –C‚O, –CH2),
2.01 (d, 1H, NH–N), 8.12 (s, 1H, N‚CH), 6.6–6.90 (m,
8H, Ar–H).13C NMR (50 MHz; CDCl3) d: 55.9 (C–
OCH3), 19.92–71.65 (Cyclohexane), 50.78 (CH), 36.4 (–
NH–CH2) 54.57 (O‚C–CH2), 143.8 (CH‚N), 114.4–163.0
(Aromatic), Anal. calcd for C24H29Cl2N3O3: C 60.25, H
6.11, N, 8.78; found C 60.20, H 6.06, N, 8.72.
6.1.3.5. 2-(2-(2, 3, 4-Trimethoxybenzylidene) hydrazinyl)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acet-
amide (4e). Yield 61%; m.p. 180–183 C, Off white color
powder, IR (KBr, cm1) 3450 (NH), 1710 (C‚O), 1654
(CONH), 1560 (N‚CH), 1H NMR: 3.76 (s, 3H, Ar–OCH3),
2.07 (d, 1H, –OH) (cyclohexanol), 1.40–1.69 (m, 10H, –CH2)
(cyclohexanol), 3.47 (dd, 1H, –CH), 3.65 (dd, –2H, –CH2),
8.05 (d, 1H, –NH–C‚O), 3.58 (d, 2H, –C‚O, –CH2), 2.04
(d, 1H, NH–N), 8.10 (s, 1H, N‚CH), 6.6–6.90 (m, 4H, Ar–H).13C NMR d: 56.02 (C–OCH3), 19.95–71.35 (Cyclohexane),
50.84 (CH), 36.9 (–NH–CH2) 54.59 (O‚C–CH2), 143.05
(CH‚N), 110.4–155.0 (Aromatic), Anal. calcd for
C27H37N3O6: C 64.91, H 7.46, N 8.41; found C 64.86, H
7.41, N 8.37.
6.1.3.6. 2-(2-(2-Chlorobenzylidene) hydrazinyl)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4f). Yield 69%; m.p. 140–145 C, Light yellow color powder,
IR (KBr, cm1) 3448 (NH), 1717 (C‚O), 1647 (CONH), 1542
(N‚CH), 1H NMR: 3.78 (s, 3H, Ar–OCH3), 2.03 (d, 1H, –
OH) (cyclohexanol), 1.42–1.70 (m, 10H, –CH2) (cyclohexanol),
3.45 (dd, 1H, –CH), 3.63 (dd, –2H, –CH2), 8.01 (d, 1H, –NH–
C‚O), 3.58 (d, 2H, –C‚O, –CH2), 2.05 (d, 1H, NH–N), 8.13
(s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–H).13C NMR d: 55.8
(C–OCH3), 19.90–71.40 (Cyclohexane), 50.85 (CH), 36.45 (–
NH–CH2) 54.59 (O‚C–CH2), 143.0 (CH‚N), 127.0.–135.0
(Aromatic), Anal. calcd for C24H30ClN3O3: C 64.93, H 6.81,
N 9.46; found C 64.90, H 6.76, N 9.41.
6.1.3.7. 2-(2-(4-Nitrobenzylidene) hydrazinyl)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4g). Yield 76%; m.p. 275–278 C, Yellow color powder, IR
(KBr, cm1) 3422 (NH), 1708 (C‚O), 1654 (CONH), 1560
(N‚CH), 1H NMR: 3.75 (s, 3H, Ar–OCH3), 2.04 (d, 1H, –
OH) (cyclohexanol), 1.42–1.68 (m, 10H, –CH2) (cyclohexanol),
3.47 (dd, 1H, –CH), 3.66 (dd, –2H, –CH2), 8.05 (d, 1H, –NH–
C‚O), 3.57 (d, 2H, –C‚O, –CH2), 2.05 (d, 1H, NH–N), 8.13
(s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–H).13C NMR d: 55.80
(C–OCH3), 19.90–71.39 (Cyclohexane), 50.85 (CH), 36.30
(–NH–CH2) 54.55 (O‚C–CH2), 143.50 (CH‚N), 121.0–
140.0 (Aromatic), Anal. calcd for C24H30N4O5: C 63.42, H
6.65, N 12.33; found C 63.37, H 6.60, N 12.30.
6.1.3.8. 2-(2-(3, 4, 5-Trimethoxybenzylidene) hydrazinyl)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acet-
amide (4h). Yield 73%; m.p. 190–197 C, off white color
powder, IR (KBr, cm1) 3448 (NH), 1743 (C‚O), 1647
(CONH), 1577 (N‚CH), 1H NMR: 3.79 (s, 3H, Ar–OCH3),
2.04 (d, 1H, –OH) (cyclohexanol), 1.40–1.70 (m, 10H, –CH2)
(cyclohexanol), 3.49 (dd, 1H, –CH), 3.64 (dd, –2H, –CH2),
8.01 (d, 1H, –NH–C‚O), 3.58 (d, 2H, –C‚O, –CH2), 2.05
(d, 1H, NH–N), 8.13 (s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–
H).13C NMR d: 55.80 (C–OCH3), 19.92–71.35 (Cyclohexane),
50.84 (CH), 36.40 (–NH–CH2) 54.57 (O‚C–CH2), 143.0
(CH‚N), 121.4–139.9 (Aromatic), Anal. calcd for
C27H37N3O6: C 64.91, H 7.46, N 8.41; found C 64.86, H
7.41, N 8.37.
6.1.3.9. 2-(2-(3-Phenoxybenzylidene) hydrazinyl)-N-(2-(1-
hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4i). Yield 70%; m.p. 130–132 C, light brown color powder,
IR (KBr, cm1) 3422 (NH), 1718 (C‚O), 1636 (CONH), 1577
(N‚CH), 1H NMR: 3.79 (s, 3H, Ar–OCH3), 2.05 (d, 1H, –
OH) (cyclohexanol), 1.42–1.69 (m, 10H, –CH2) (cyclohexanol),
3.48 (dd, 1H, –CH), 3.66 (dd, –2H, –CH2), 8.01 (d, 1H, –NH–
C‚O), 3.57 (d, 2H, –C‚O, –CH2), 2.05 (d, 1H, NH–N), 8.13
(s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–H).13C NMR d: 55.85
(C–OCH3), 19.75–71.50 (Cyclohexane), 50.75 (CH), 36.45
(–NH–CH2) 54.55 (O‚C–CH2), 143.20 (CH‚N), 119.4–
160.0 (Aromatic), Anal. calcd for C30H35N3O4: C 71.83, H
7.03, N 8.38; found C 71.79, H 7.00, N 8.33.
S810 V. Mahyavanshi et al.6.1.3.10. 2-(2-(4-Dimethylaminobenzylidene) hydrazinyl)-N-
(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetam-
ide (4j). Yield 74%; m.p. 229–232 C, off white color powder,
IR (KBr, cm1) 3422 (NH), 1734 (C‚O), 1637 (CONH), 1578
(N‚CH), 1H NMR: 3.75 (s, 3H, Ar–OCH3), 2.03 (d, 1H,
–OH) (cyclohexanol), 1.41–1.75 (m, 10H, –CH2) (cyclohexa-
nol), 3.49 (dd, 1H, –CH), 3.68 (dd, –2H, –CH2), 8.09 (d, 1H,
–NH–C‚O), 3.58 (d, 2H, –C‚O, –CH2), 2.05 (d, 1H, NH–
N), 8.13 (s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–H).13C NMR
d: 55.84 (C–OCH3), 19.90–71.44 (Cyclohexane), 50.84 (CH),
36.37 (–NH–CH2) 54.58 (O‚C–CH2), 143.5 (CH‚N),
114.4–163.0 (Aromatic), Anal. calcd for C26H36N4O3:
C 69.00, H 8.02, N 12.38; found C 68.95, H 8.00, N 12.34.
6.1.3.11. 2-(2-(4-Hydroxy3-methoxybenzylidene) hydrazinyl)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acet-
amide (4k). Yield 75%; m.p. 218–222 C, orange color pow-
der, IR (KBr, cm1) 3462 (NH), 1718 (C‚O), 1648
(CONH), 1571 (N‚CH), 1H NMR: 3.76 (s, 3H, Ar–OCH3),
2.05 (d, 1H, –OH) (cyclohexanol), 1.41–1.67 (m, 10H, –CH2)
(cyclohexanol), 3.48 (dd, 1H, –CH), 3.65 (dd, –2H, –CH2),
8.03 (d, 1H, –NH–C‚O), 3.55 (d, 2H, –C‚O, –CH2), 2.06
(d, 1H, NH–N), 8.13 (s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–
H).13C NMR d: 55.9 (C–OCH3), 19.92–71.65 (Cyclohexane),
50.78 (CH), 36.4 (–NH–CH2) 54.57 (O‚C–CH2), 143.8
(CH‚N), 114.4–163.0 (Aromatic), Anal. calcd for
C25H33N3O5: C 65.91, H 7.30, N 9.22; found C 65.86, H
7.26, N 9.18.
6.1.3.12. 2-(2-(3-Bromo-4-methoxybenzylidene) hydrazinyl)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acet-
amide (4l). Yield 70%; m.p. 133–137 C, light yellow color
powder, IR (KBr, cm1) 3468 (NH), 1735 (C‚O), 1647
(CONH), 1570 (N‚CH), 1H NMR: 3.76 (s, 3H, Ar–OCH3),
2.05 (d, 1H, –OH) (cyclohexanol), 1.41–1.69 (m, 10H, –CH2)
(cyclohexanol), 3.48 (dd, 1H, –CH), 3.68 (dd, –2H, –CH2),
8.04 (d, 1H, –NH–C‚O), 3.57 (d, 2H, –C‚O, –CH2), 2.07
(d, 1H, NH–N), 8.10 (s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–
H).13C NMR d: 55.5 (C–OCH3), 19.90–71.50 (Cyclohexane),
50.85 (CH), 36.9 (–NH–CH2) 54.55 (O‚C–CH2), 143.4
(CH‚N), 116.4–135.0 (Aromatic), 159.8 (C–Br), Anal. calcd
for C25H32BrN3O4: C 57.92, H 6.22, N 8.11; found C 57.86,
H 6.17, N 8.07.
6.1.3.13. 2-(2-(2-Nitrobenzylidene) hydrazinyl)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4m). Yield 77%; m.p. 206–212 C, yellow color powder IR
(KBr, cm1) 3465 (NH), 1734 (C‚O), 1649 (CONH), 1565
(N‚CH), 1H NMR: 3.77 (s, 3H, Ar–OCH3), 2.04 (d, 1H, –
OH) (cyclohexanol), 1.41–1.69 (m, 10H, –CH2) (cyclohexanol),
3.47 (dd, 1H, –CH), 3.65 (dd, –2H, –CH2), 8.09 (d, 1H, –NH–
C‚O), 3.58 (d, 2H, –C‚O, – CH2), 2.05 (d, 1H, NH–N), 8.14
(s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–H).13C NMR d: 55.2
(C–OCH3), 19.9–71.3 (Cyclohexane), 50.81 (CH), 36.5
(–NH–CH2) 54.87 (O‚C–CH2), 143.1 (CH‚N), 121.4–140.0
(Aromatic), Anal. calcd for C24H30N4O5: C 63.42, H 6.65, N
12.33; found C 63.37, H 6.60, N 12.29.
6.1.3.14. 2-(2-(3-Chlorobenzylidene) hydrazinyl)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetamide
(4n). Yield 74%; m.p. 206–212 C, light brown color powder,
IR (KBr, cm1) 3461 (NH), 1737 (C‚O), 1650 (CONH), 1571(N‚CH), 1H NMR: 3.73 (s, 3H, Ar–OCH3), 2.05 (d, 1H, –
OH) (cyclohexanol), 1.40–1.69 (m, 10H, –CH2) (cyclohexanol),
3.48 (dd, 1H, –CH), 3.64 (dd, –2H, –CH2), 8.05 (d, 1H, –NH–
C‚O), 3.58 (d, 2H, –C‚O, –CH2), 2.05 (d, 1H, NH–N), 8.12
(s, 1H, N‚CH), 6.6–6.90 (m, 8H, Ar–H).13C NMR d: 55.30
(C–OCH3), 19.95–71.45 (Cyclohexane), 50.80 (CH), 36.45
(–NH–CH2) 54.70 (O‚C–CH2), 143.0 (CH‚N), 124.4–140.0
(Aromatic), Anal. calcd for C24H30ClN3O3: C 64.93, H 6.81,
N 9.46; found C 64.89, H 6.76, N 9.41.
6.1.4. General preparation of the compounds (5a–n)
A mixture of compound 4a–n (0.01 mol) and thioglycolic acid
(0.02 mol) was reﬂuxed in the presence of zinc chloride and sol-
vent DMF for 12 h. The completion of reaction was monitored
by TLC (toluene: acetone, 5.0:5.0). After completion, reaction
mass was dumped in ice cold water. The product formed was
isolated washed with water and recrystallized from ethanol
to give compound 5a–n.
6.1.4.1. 2-(2-(4-Hydroxyphenyl)-4-oxothiazolidin-3-ylamino)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acet-
amide (5a). Yield 58%; m.p. 96–97 C, off white color
powder, IR (KBr, cm1) 3483 (–OH), 1734 (C‚O thiazolidi-
none), 1654 (CONH), 625 (C–S–C), 1H NMR 3.73 (s, 3H,
Ar–OCH3), 2.01 (s, 1H, –OH) (Cyclohexane), 1.41–1.67 (m,
10H, –CH2) (Cyclohexane), 3.45 (dd, 1H, –CH), 3.61 (dd,
2H, CH2), 8.01 (d, 1H, –NH–C‚O), 3.53 (d, 2H, O‚C–
CH2), 2.01 (d, 1H, –NH–N), 5.93 (s, 1H, N–CH thiazolidi-
none), 3.37 (s, 2H, –CH2 (thiazolidinone), ring), 3.73 (s, 1H,
Ar–OCH3), 6.6–6.90 (m, 8H, Ar–H),
13C NMR 55.5 (O–
CH3), 168.55 (C‚O), 57.19 (CHS); 115.0–159.0 (Aromatic),
MS (m/z): 501 (M+), Anal. Calcd for C26H33N3O5S: C
62.50. H 6.66, N 8.41; found C 62.00, H 6.61, N 8.36.
6.1.4.2. 2-(2-(4-Methoxyphenyl)-4-oxothiazolidin-3-ylamino)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)acet-
amide (5b). Yield 50%; m.p. 280 C, off white color powder,
IR (KBr, cm1) 3484 (–OH), 1735 (C‚O thiazolidinone),
1647 (CONH), 626 (C–S–C), 1H NMR 3.74 (s, 3H, Ar–
OCH3), 2.02 (s, 1H, –OH) (Cyclohexane), 1.41–1.67 (m,
10H, –CH2) (Cyclohexane), 3.47 (dd, 1H, –CH), 3.60 (dd,
2H, CH2), 8.01 (d, 1H, –NH–C‚O), 3.53 (d, 2H, O‚C–
CH2), 2.01 (d, 1H, –NH–N), 5.93 (s, 1H, N–CH thiazolidi-
none), 3.38 (s, 2H, –CH2 (thiazolidinone ring), 5.90 (s, 1H,
Ar–OH), 6.6–6.90 (m, 8H, Ar–H).13C NMR (50 MHz; CDCl3)
d: 169.20 (C‚O), 156.10 (C–OH), 57.54 (–OCH3), 57.14
(CHS); 115.0–160.0 (Aromatic), MS (m/z): 514.70 (M+), Anal.
Calcd for C26H33N3O5S: C 63.13, H 6.87, N 8.18; found C
63.09, H 6.61, N 8.14.
6.1.4.3. 2-(4-Oxo-2-phenylthiazolidin-3-ylamino)-N-(2-
(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)acetamide
(5c). Yield 53%; m.p. 80–85 C, off white color powder, IR
(KBr, cm1) 3471 (–OH), 1735 (C‚O thiazolidinone), 16/54
(CONH), 625 (C–S–C), 1H NMR 3.73 (s, 3H, Ar–OCH3),
2.01 (s, 1H, –OH) (Cyclohexane), 1.41–1.68 (m, 10H, –CH2)
(Cyclohexane), 3.48 (dd, 1H, –CH), 3.63 (dd, 2H, CH2), 8.00
(d, 1H, –NH–C‚O), 3.55 (d, 2H, O‚C–CH2), 2.01 (d, 1H,
–NH–N), 5.93 (s, 1H, N–CH thiazolidinone), 3.38 (s, 2H, –
CH2 (thiazolidinone ring), 6.6–6.90 (m, 8H, Ar–H),
13C
NMR (50 MHz; CDCl3) d: 55.9 (O–CH3), 168.20 (C‚O),
57.54 (–OCH3), 57.14 (CHS); 115.0–160.0 (Aromatic), MS
Synthesis and pharmacological studies of 1-(2-amino-1-(4-methoxyphenyl) ethyl) cyclohex anol S811(m/z): 484.5 (M+), Anal. Calcd for C26H33N3O4S: C 64.57, H
6.88, N 8.69; found C 64.52, H 6.82, N 8.65.
6.1.4.4. 2-(2-(2,3-Dichlorophenyl)-4-oxothiazolidin-3-ylami-
no)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)
acetamide (5d). Yield 59%; m.p. >300 C; Brown color pow-
der, IR (KBr, cm1) 3481 (–OH), 1737 (C‚O thiazolidinone),
1648 (CONH), 620 (C–S–C), 1H NMR 3.75 (s, 3H, Ar–
OCH3), 2.01 (s, 1H, –OH) (Cyclohexane), 1.43–1.69 (m,
10H, –CH2) (Cyclohexane), 3.46 (dd, 1H, –CH), 3.65 (dd,
2H, CH2), 8.03 (d, 1H, –NH–C‚O), 3.56 (d, 2H, O‚C–
CH2), 2.01 (d, 1H, –NH–N), 5.95 (s, 1H, N–CH thiazolidi-
none), 3.38 (s, 2H, –CH2 (thiazolidinone ring), 6.8–7.03 (m,
8H, Ar–H), 13C NMR 55.8 (O–CH3), 168.10 (C‚O), 48.50
(CHS); 115.0–159.0 (Aromatic), MS (m/z): 553.5, 555.5
(M+2), Anal. Calcd for C26H31Cl2N3O4S: C 56.52, H 5.66,
N 7.61; found C 56.46, H 5.61, N 7.55.
6.1.4.5. 2-(2-(2,3,4-Trimethoxyphenyl)-4-oxothiazolidin-3-yla-
mino)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)
acetamide (5e). Yield 52%; m.p. 65–70 C, light yellow color
powder, IR (KBr, cm1) 3471 (–OH), 1730 (C‚O thiazolidi-
none), 1655 (CONH), 623 (C–S–C), 1H NMR 3.74 (s, 3H,
Ar–OCH3), 2.03 (s, 1H, –OH) (Cyclohexane), 1.41–1.67 (m,
10H, –CH2) (Cyclohexane), 3.45 (dd, 1H, –CH), 3.62 (dd,
2H, CH2), 8.01 (d, 1H, –NH–C‚O), 3.53 (d, 2H, O‚C–
CH2), 2.01 (d, 1H, –NH–N), 5.93 (s, 1H, N–CH thiazolidi-
none), 3.38 (s, 2H, –CH2 (thiazolidinone ring), 3.73 (s, 3H,
Ar–OCH3), 6.6–6.90 (m, 8H, Ar–H),
13C NMR 55.95 (O–
CH3), 168.70 (C‚O), 47.55 (CHS); 107.0–155.0 (Aromatic),
MS (m/z): 501 (M+), Anal. Calcd for C29H39N3O7S: C
60.71, H 6.85, N 7.32; found C 60.66, H 6.81, N 7.28.
6.1.4.6. 2-(2-(2-chlorophenyl)-4-oxothiazolidin-3-ylamino)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)acet-
amide (5f). Yield 55%; m.p. 80–90 C; light brown color
powder, IR (KBr, cm1) 3449 (–OH), 1718 (C‚O thiazolidi-
none), 1654 (CONH), 621 (C–S–C), 1H NMR 3.73 (s, 3H,
Ar–OCH3), 2.00 (s, 1H, –OH) (Cyclohexane), 1.40–1.68 (m,
10H, –CH2) (Cyclohexane), 3.47 (dd, 1H, –CH), 3.65 (dd,
2H, CH2), 8.04 (d, 1H, –NH–C‚O), 3.55 (d, 2H, O‚C–
CH2), 2.01 (d, 1H, –NH–N), 5.92 (s, 1H, N–CH thiazolidi-
none), 38 (s, 2H, –CH2 (thiazolidinone ring), 7.0–7.16 (m,
8H, Ar–H), 13C NMR 55.91 (O–CH3), 168.70 (C‚O), 48.00
(CHS); 135.01 (C–Cl), 125.0–149.0 (Aromatic). MS (m/z):
519 (M+), 521 (M+2), Anal. Calcd for C26H32ClN3O4S: C
60.28, H 6.23, N, 8.11; found C 60.23, H 6.19, N, 8.06.
6.1.4.7. 2-(2-(4-nitrophenyl)-4-oxothiazolidin-3-ylamino)-N-
(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)acetam-
ide (5g). Yield (54%); m.p. 70–75 C, off white color powder,
IR (KBr, cm1) 3471 (–OH), 1735 (C‚O thiazolidinone), 1661
(CONH), 627 (C–S–C), 1H NMR 3.75 (s, 3H, Ar–OCH3), 2.01
(s, 1H, –OH) (Cyclohexane), 1.42–1.68 (m, 10H, –CH2)
(Cyclohexane), 3.47 (dd, 1H, –CH), 3.65 (dd, 2H, CH2), 8.01
(d, 1H, –NH–C‚O), 3.55 (d, 2H, O‚C–CH2), 2.01 (d, 1H,
–NH–N), 5.95 (s, 1H, N–CH thiazolidinone), 3.39 (s, 2H,
–CH2 (thiazolidinone ring), 3.73 (s, 3H, Ar–OCH3), 7.36–
8.09 (m, 8H, Ar–H), 13C NMR 55.90 (O–CH3), 168.80
(C‚O), 57.50 (CHS); 120.0–146.0 (Aromatic), MS (m/z): 530(M+), Anal. Calcd for C26H32N4O6S: C 59.07, H 6.10, N
10.60; found C 59.02, H 6.05, N 10.56.
6.1.4.8. 2-(2-(3,4,5-trimethoxyphenyl)-4-oxothiazolidin-3-yla-
mino)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxy-
phenyl)ethyl)acetamide (5h). Yield 60%; m.p. 140–145 C;
light brown color powder, IR (KBr, cm1) 3477 (–OH), 1734
(C‚O thiazolidinone), 1636 (CONH), 623 (C–S–C), 1H
NMR 3.74 (s, 3H, Ar–OCH3), 2.03 (s, 1H, –OH) (Cyclohex-
ane), 1.41–1.67 (m, 10H, –CH2) (Cyclohexane), 3.45 (dd, 1H,
–CH), 3.62 (dd, 2H, CH2), 8.01 (d, 1H, –NH–C‚O), 3.53
(d, 2H, O‚C–CH2), 2.01 (d, 1H, –NH–N), 5.93 (s, 1H, N–
CH thiazolidinone), 3.38 (s, 2H, –CH2 (thiazolidinone ring),
3.73 (s, 3H, Ar–OCH3), 6.6–6.90 (m, 8H, Ar–H),
13C NMR
55.82 (O–CH3), 169.10 (C‚O), 58.10 (CHS); 105.0–151.0
(Aromatic), MS (m/z): 575 (M+), Anal. Calcd for
C29H39N3O7S: C 60.71, H 6.85, N 7.32; found C 60.66, H
6.81, N 7.28.
6.1.4.9. 2-(4-oxo-2-(3-phenoxyphenyl) thiazolidin-3-ylamino)-
N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acet-
amide (5i). Yield 60%; m.p. 55 C; off white color powder, IR
(KBr, cm1) 3477 (–OH), 1734 (C‚O thiazolidinone), 1654
(CONH), 620 (C–S–C), 1H NMR 3.74 (s, 3H, Ar–OCH3),
2.00 (s, 1H, –OH) (Cyclohexane), 1.44–1.69 (m, 10H, –CH2)
(Cyclohexane), 3.47 (dd, 1H, –CH), 3.64 (dd, 2H, CH2), 8.00
(d, 1H, –NH–C‚O), 3.55 (d, 2H, O‚C–CH2), 2.01 (d, 1H,
–NH–N), 5.92 (s, 1H, N–CH thiazolidinone), 3.40 (s, 2H, –
CH2 (thiazolidinone ring), 3.73 (s, 3H, Ar–OCH3), 6.72–7.34
(m, 16H, Ar–H), 13C NMR 55.92 (O–CH3), 168.80 (C‚O),
57.50 (CHS); 115.0–158.0 (Aromatic), MS (m/z): 577 (M+),
Anal. Calcd for C32H37N3O5S: C 66.76, H 6.48, N, 7.30; found
C 66.71, H 6.42, N, 7.25.
6.1.4.10. 2-(2-(4-(dimethylamino) phenyl)-4-oxothiazolidin-
3-ylamino)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)
ethyl) acetamide (5j). Yield 61%; m.p. 130–135 C; light
brown color powder, IR (KBr, cm1) 3475 (–OH), 1718
(C‚O thiazolidinone), 1654 (CONH), 622 (C–S–C), 1H
NMR 3.73 (s, 3H, Ar–OCH3), 2.02 (s, 1H, –OH) (Cyclohex-
ane), 1.43–1.69 (m, 10H, –CH2) (Cyclohexane), 3.46 (dd, 1H,
–CH), 3.62 (dd, 2H, CH2), 8.01 (d, 1H, –NH–C‚O), 3.55
(d, 2H, O‚C–CH2), 2.01 (d, 1H, –NH–N), 5.93 (s, 1H, N–
CH thiazolidinone), 3.40 (s, 2H, –CH2 (thiazolidinone ring),
2.86 (s, 2H, Ar–NH2), 6.47–6.89 (m, 8H, Ar–H),
13C NMR
56.2 (O–CH3), 168.00 (C‚O), 57.50 (CHS); 115.0–148.0 (Aro-
matic), MS (m/z): 528 (M+), Anal. Calcd for C28H38N4O4S: C
63.85, H 7.27, N 10.64; found C 63.80, H 7.22, N 10.60.
6.1.4.11. 2-(2-(4-hydroxy-3-methoxyphenyl)-4-oxothiazolidin-
3-ylamino)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)
ethyl)acetamide (5k). Yield 59%; m.p. 40–45 C; off white col-
or powder, IR (KBr, cm1) 3469 (–OH), 1718 (C‚O thiazolid-
inone), 1648 (CONH), 621 (C–S–C), 1H NMR 3.75 (s, 3H, Ar–
OCH3), 2.05 (s, 1H, –OH) (Cyclohexane), 1.42–1.69 (m, 10H, –
CH2) (Cyclohexane), 3.45 (dd, 1H, –CH), 3.62 (dd, 2H, CH2),
8.01 (d, 1H, –NH–C‚O), 3.53 (d, 2H, O‚C–CH2), 2.01 (d,
1H, –NH–N), 5.91 (s, 1H, N–CH thiazolidinone), 3.39 (s,
2H, –CH2 (thiazolidinone ring), 5.01 (s, 1H, Ar–OH), 6.40–
6.55 (m, 6H, Ar–H), 13C NMR 56.8 (O–CH3), 168.9 (C‚O),
57.90 (CHS); 114.0–150.0 (Aromatic), MS (m/z): 531 (M+),
S812 V. Mahyavanshi et al.Anal. Calcd for C27H35N3O6S: C 61.23, H 6.66, N 7.93; found
C 61.19, H 6.61, N 7.89.
6.1.4.12. 2-(2-(3-bromo-4-methoxyphenyl)-4-oxothiazolidin-
3-ylamino)-N-(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)
ethyl)acetamide (5l). Yield 59%; m.p. 75–80 C; light brown
color powder, IR (KBr, cm1) 3481 (–OH), 1740 (C‚O thia-
zolidinone), 1649 (CONH), 625 (C–S–C), 1H NMR 3.75 (s,
3H, Ar–OCH3), 2.02 (s, 1H, –OH) (Cyclohexane), 1.42–1.68
(m, 10H, –CH2) (Cyclohexane), 3.46 (dd, 1H, –CH), 3.61
(dd, 2H, CH2), 8.01 (d, 1H, –NH–C‚O), 3.53 (d, 2H,
O‚C–CH2), 2.01 (d, 1H, –NH–N), 5.92 (s, 1H, N–CH thiazo-
lidinone), 3.39 (s, 2H, –CH2 (thiazolidinone) ring), 3.73 (s, 3H,
Ar–OCH3), 6.87–7.15 (m, 6H, Ar–H),
13C NMR 55.7 (O–
CH3), 168.80 (C‚O), 56.50 (CHS), 112.2 (C–Br), 115.0–
149.0 (Aromatic), MS (m/z): 594 (M+) 596 (M+2), Anal.
Calcd for C27H34BrN3O5S: C 54.73, H 5.78, N 7.09; found C
54.59, H 5.71, N 7.02.
6.1.4.13. 2-(2-(2-nitrophenyl)-4-oxothiazolidin-3-ylamino)-N-
(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl)acetam-
ide (5m). Yield 59%; m.p. 208–210 C; pale yellow color pow-
der, IR (KBr, cm1) 3479 (–OH), 1730 (C‚O thiazolidinone),
1647 (CONH), 628 (C–S–C), 1H NMR 3.73 (s, 3H, Ar–
OCH3), 2.00 (s, 1H, –OH) (Cyclohexane), 1.41–1.67 (m,
10H, –CH2) (Cyclohexane), 3.46 (dd, 1H, –CH), 3.62 (dd,
2H, CH2), 8.05 (d, 1H, –NH–C‚O), 3.56 (d, 2H, O‚C–
CH2), 2.01 (d, 1H, –NH–N), 5.95 (s, 1H, N–CH thiazolidi-
none), 3.40 (s, 2H, –CH2 (thiazolidinone ring), 7.31–8.08 (m,
8H, Ar–H), 13C NMR 55.80 (O–CH3), 168.80 (C‚O), 48.40
(CHS); 125.0–148.90 (Aromatic), MS (m/z): 530 (M+), Anal.
Calcd for C26H32N4O6S: C 59.07, H 6.10, N 10.60; found C
59.02, H 6.06, N 10.55.
6.1.4.14. 2-(2-(3-chlorophenyl)-4-oxothiazolidin-3-ylamino)-N-
(2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl) ethyl) acetam-
ide (5n). Yield 59%; m.p. 180–185 C, pale yellow color pow-
der, IR (KBr, cm1) 3490 (–OH), 1731 (C‚O thiazolidinone),
1654 (CONH), 618 (C–S–C), 1H NMR 3.74 (s, 3H, Ar–
OCH3), 2.05 (s, 1H, –OH) (Cyclohexane), 1.41–1.69 (m,
10H, –CH2) (Cyclohexane), 3.46 (dd, 1H, –CH), 3.65 (dd,
2H, CH2), 8.06 (d, 1H, –NH–C‚O), 3.56 (d, 2H, O‚C–
CH2), 2.07 (d, 1H, –NH–N), 5.97 (s, 1H, N–CH thiazolidi-
none), 3.40 (s, 2H, –CH2 (thiazolidinone ring), 6.95–7.10 (m,
8H, Ar–H), 13C NMR 55.8 (O–CH3), 168.01 (C‚O), 56.50
(CHS); 135.01 (C–Cl), 125.0–149.0 (Aromatic), MS (m/z):
519 (M+) 521 (M+2), Anal. Calcd for C26H32ClN3O4S: C
60.28, H 6.23, N 8.11; found C 60.23, H 6.19, N 8.06.6.2. Biological assay
6.2.1. In vitro evaluation of antimicrobial activity
The MICs of synthesized compounds were carried out by
broth micro dilution method as described by the European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) Anargyros et al., 1990; Shah et al., 1985; Desai
et al., 1984. Antibacterial activity was screened against two
gram positive bacteria (S. aureus ATCC 6538P, and Strepto-
coccus pyogenes ATCC 8668) and two gram negative bacteria
(E. coli ATCC 8739, and P. aeruginosa ATCC 9027). Ampicil-
lin was used as a standard antibacterial agent. Antifungalactivity was screened against three fungal species C. albicans
ATCC 10231, A. niger ATCC 16404 and A. clavatus ATCC
9600. Greseofulvin was used as a standard antifungal agent.
All ATCC cultures were collected from the National Chem-
ical Laboratory, Pune and tested against above mentioned
known drugs. The cup well plate method using Hi-Media agar
medium was employed to study the antibacterial activity of
4a–n and 5a–n against S. aureus (ATCC 6538P), P. aeruginosa
(ATCC 9027) and E. coli (ATCC 8739) EUCAST; Rattan,
2000. Preparation of nutrient broth, subculture, base layer
medium, agar medium and peptone water was done as per
the standard procedure. Each test compound (50 mg) was dis-
solved in dimethyl formamide (50 mL, 1000 lg/mL), which
was used as sample solution. Sample size for all the com-
pounds was ﬁxed at 0.1 mL. Using a sterilized cork borer cups
were scooped out of agar medium contained in a Petri dish
which was previously inoculated with the microorganisms.
The test compound solution (0.1 mL) was added in the cups
and the Petri dishes were subsequently incubated at 37 C
for 24 h. Ampicillin and Penicillin-G were used as reference
drugs and dimethyl formamide as a negative control. Zones
of inhibition produced by each compound were measured in
mm, and the results are listed in Table 1.
The antifungal activity of compounds 4a–n and 5a–n has
been assayed in vitro at concentrations of 128, 256 and
512 lg/mL against C. albicans (ATCC 10231). Inoculums of
std. suspension (0.1 ml) of test organism were added. The
plates of sabouraud dextrose agar were incubated at 22 C
for 48 h, which were maintained on sabouraud dextrose agar
slants stored at 4 C.
The compounds were tested by Cup well Method14 on Mul-
ler Hinton Agar for bacteria 4 on sabouraud dextrose agar for
yeast or antifungal at concentration of 128, 256 and 512 lg/
mL against two Gram negative & a Gram positive bacteria
and yeast. The following results were obtained.
6.2.2. Antitubercular activity
Drug susceptibility and determination of MIC of the test com-
pounds against M. tuberculosis H37Rv were performed by L.J.
agar (MIC)methodAnargyros et al., 1990; Shah et al., 1985;De-
sai et al., 1984 where primary 512, 256 and secondary 128, 64.0,
32.0, 16.0, 8.0, 4.0, 2.0 lg/ml dilutions of each test compound
were added liquid L.J. Medium and then media were sterilized
by inspissation method. A culture of M. tuberculosis H37Rv
growing on L.J. medium was harvested in 0.85% saline in bijou
bottles. These tubes were then incubated at 37 C for 24 h fol-
lowed by streaking of M. tuberculosis H37Rv (5 · 104 bacilli
per tube). These tubes were then incubated at 37 C. Growth
of bacilli was seen after 12 days, 22 days and ﬁnally 28 days of
incubation. Tubes having the compounds were compared with
control tubes wheremedium alone was incubatedwithM. tuber-
culosis H37Rv. The concentration at which no development of
colonies occurred or<20 colonies was taken asMIC concentra-
tion of the test compound. The standard strainM. tuberculosis
H37Rv was tested with known drug Rifampicin.Acknowledgements
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